Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

@article{Gaudreault2005PreclinicalPO,
  title={Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.},
  author={Jacques Gaudreault and David Fei and Jeriza Rusit and Pamela Suboc and Vanessa Shiu},
  journal={Investigative ophthalmology & visual science},
  year={2005},
  volume={46 2},
  pages={726-33}
}
PURPOSE Ranibizumab (rhuFab V2; Lucentis, Genentech, South San Francisco, CA) is a humanized monoclonal antibody fragment designed to bind all forms of VEGF, thereby blocking vessel permeability and angiogenesis in neovascular age-related macular degeneration. This study evaluated the pharmacokinetic (PK) and serum bioavailability of ranibizumab after a single intravitreal (ITV) or intravenous (IV) dose in cynomolgus monkeys. METHODS Monkeys received ranibizumab as either a bilateral ITV dose… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
172 Citations
38 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 172 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Pharmacokinetics and retinal distribution of AMD rhufab V2 after intravitreal administration in rabbits

  • J Gaudreault, W Webb, M Van Hoy
  • AAPS Pharm Sci
  • 1999
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…